anti-PD-L1/TGF-beta bispecific antibody Y101D

{
  "id": "MLC-T-ONC-011030",
  "term": "anti-PD-L1/TGF-beta bispecific antibody Y101D",
  "field": "Oncology and biomedicine",
  "definition": "A recombinant bispecific antibody targeting both the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the human transforming growth factor beta (TGF-beta), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, the anti-PD-L1/TGF-beta bispecific antibody Y101D targets, binds to and neutralizes TGFbeta while simultaneously targets, binds to, and inhibits the activity of PD-L1 on tumor cells. This prevents both TGF-beta- and PD-L1-mediated immuno-suppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This restores and enhances anti-tumor responses and inhibits tumor cell proliferation in susceptible tumor cells. TGF-beta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.",
  "synonyms": [
    "anti-PD-L1/anti-TGF-beta bispecific antibody Y101D",
    "PD-L1/TGF-beta bispecific antibody Y101D",
    "PD-L1 x TGFbeta bispecific antibody Y101D"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-pd-l1-tgf-beta-bispecific-antibody-y101d/"
}